PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas. Arrowhead sees the technology platform as an attractive candidate around which to form a new majority-owned subsidiary to steer the technology through clinical development.